TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Laboratory Animals
2.2. Oral Glucose Tolerance Test in Trpv1−/− Mice
2.3. Glucose-Stimulated Early Insulin Secretion in Trpv1−/− Mice
2.4. Determination Of Pancreatic β-Cell Mass and TRPV1-Like Immunoreactivity in Trpv1−/− Mice and their Controls
2.5. Oral Glucose Tolerance Test and Glucose-Stimulated Insulin Secretion in Zucker Obese Rats Treated with the TRPV1 Antagonist, BCTC
2.6. Measurement of Mesenteric Adipose Tissue Inflammatory Markers in Zucker Obese Rats Following a Single Dose BCTC
2.7. Analysis of Blood Glucose and Plasma Insulin
2.8. Statistical Methods
3. Results
3.1. Trpv1−/− Mice on High-Fat Diet
3.2. The Effect of Pharmacological TRPV1 Antagonism by BCTC on Glucose Metabolism and Mesenteric Adipose Tissue Inflammatory Marker Generation
4. Discussion
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Umpierrez, G.E. (Ed.) Therapy for Diabetes Mellitus and Related Disorders, 6th ed.; American Diabetes Association: San Francisco, CA, USA, 2014. [Google Scholar]
- Seuring, T.; Archangelidi, O.; Suhrcke, M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics 2015, 33, 811–831. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- The World Health Organization. Fact Sheets: Diabetes. Available online: http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed on 10 July 2019).
- Pop, L.M.; Lingvay, I. The infamous, famous sulfonylureas and cardiovascular safety: Much ado about nothing? Curr. Diab. Rep. 2017, 17, 124–132. [Google Scholar] [CrossRef] [PubMed]
- Mazidi, M.; Rezaie, P.; Gao, H.; Kengne, A.P. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. J. Am. Hear. Assoc. 2017, 6, e004007. [Google Scholar] [CrossRef] [PubMed]
- Lamos, E.L.; A Stein, S.; Davis, S.N. Sulfonylureas and meglitinides: historical and contemporary issues. Panminerva Med. 2013, 55, 239–251. [Google Scholar] [PubMed]
- Goltsman, I.; Khoury, E.E.; Winaver, J.; Abassi, Z. Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure? Pharmacol. Ther. 2016, 168, 75–97. [Google Scholar] [CrossRef]
- Nassif, M.; Kosiborod, M. Effect of glucose-lowering therapies on heart failure. Nat. Rev. Cardiol. 2018, 15, 282–291. [Google Scholar] [CrossRef] [PubMed]
- Drugs.com. Empagliflozin Side Effects. Available online: https://www.drugs.com/sfx/empagliflozin-side-effects.html (accessed on 10 July 2019).
- Frasca, D.; Blomberg, B.B.; Paganelli, R. Aging, Obesity, and Inflammatory Age-Related Diseases. Front. Immunol. 2017, 8, 1745. [Google Scholar] [CrossRef] [PubMed]
- Gram, D.X.; Holst, J.J.; Szallasi, A. TRPV1: A potential therapeutic target in type 2 diabetes and co-morbidities? Trends Mol. Med. 2017, 23, 1002–1013. [Google Scholar] [CrossRef]
- Koopmans, S.J.; Leighton, B.; DeFronzo, R.A. Neonatal deafferentiation of capsaicin-sensitive sensory nerves increases in vivo insulin sensitivity in conscious adult rats. Diabetologia 1998, 41, 813–820. [Google Scholar] [CrossRef]
- Gram, D.X.; Ahren, B.; Nagy, I.; Olsen, U.B.; Brand, C.L.; Sundler, F.; Tabanera, R.; Svendsen, O.; Carr, R.D.; Santha, P.; et al. Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in Zucker diabetic rat, an animal model for some aspects of human type 2 diabetes. Eur. J. Neurosci. 2007, 25, 213–223. [Google Scholar] [CrossRef]
- Gram, D.X.; Hansen, A.J.; Wilken, M.; Elm, T.; Svendsen, O.; Carr, R.D.; Ahrén, B.; Brand, C.L. Plasma calcitonin gene-related peptide is increased prior to the onset of obesity, and sensory denervation by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur. J. Endocrinol. 2005, 153, 963–969. [Google Scholar] [CrossRef] [PubMed]
- Ishizuka, J.; Greeley, G.H., Jr.; Cooper, C.W.; Thompson, J.C. Effect of calcitonin gene-related peptide on glucose and gastric inhibitory polypeptide-stimulated insulin release from cultured newborn and adult rat islet cells. Regul. Pept. 1988, 20, 73–82. [Google Scholar] [CrossRef]
- Wick, E.C.; Hoge, S.G.; Grahn, S.W.; Kim, E.; Divino, L.A.; Grady, E.F.; Bunnett, N.W.; Kirkwood, K.S. Transient receptor potential vanilloid 1, calcitonin gene-related peptide, and substance P mediate nociception in acute pancreatitis. Am. J. Physiol. Liver Physiol. 2006, 290, G959–G969. [Google Scholar] [CrossRef] [PubMed]
- Szallasi, A.; Blumberg, P.M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev. 1999, 51, 159–212. [Google Scholar] [PubMed]
- Zucker, T.F.; Zucker, L.M. Hereditary Obesity in the Rat Associated with High Serum Fat and Cholesterol. Exp. Boil. Med. 1962, 110, 165–171. [Google Scholar] [CrossRef]
- McCaleb, M.L.; Sredy, J. Metabolic abnormalities of the hyperglycemic obese Zucker rat. Metabolism 1992, 41, 522–525. [Google Scholar] [CrossRef]
- Hello Bio. BCTC (HB1190). Available online: https://www.hellobio.com/bctc.html (accessed on 10 July 2019).
- Correll, C.C.; Phelps, P.T.; Anthes, J.C.; Umland, S.; Greenfeder, S. Cloning and pharmacological characterization of mouse TRPV1. Neurosci. Lett. 2004, 370, 55–60. [Google Scholar] [CrossRef]
- Behrendt, H.J.; Germann, T.; Gillen, C.; Hatt, H.; Jostock, R. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPS) assay. Eur. J. Pharmacol. 2004, 141, 737–745. [Google Scholar] [CrossRef]
- Fajardo, O.; Meseguer, V.; Belmonte, C.; Viana, F. TRPA1 Channels Mediate Cold Temperature Sensing in Mammalian Vagal Sensory Neurons: Pharmacological and Genetic Evidence. J. Neurosci. 2008, 28, 7863–7875. [Google Scholar] [CrossRef] [Green Version]
- Valenzano, K.J.; Grant, E.R.; Wu, G.; Hachicha, M.; Schmid, L.; Tafesse, L.; Sun, Q.; Rotshteyn, Y.; Francis, J.; Limberis, J.; et al. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J. Pharmacol. Exp. Ther. 2001, 306, 377–386. [Google Scholar] [CrossRef]
- Pomonis, J.D.; Harrison, J.E.; Mark, L.; Bristol, D.R.; Valenzano, K.J.; Walker, K. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 2003, 306, 387–393. [Google Scholar] [PubMed]
- Tanaka, H.; Shimaya, A.; Kiso, T.; Kuramochi, T.; Shimokawa, T.; Shibasaki, M. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci. 2011, 88, 559–563. [Google Scholar] [CrossRef] [PubMed]
- Fredin, M.F.; Kjellstedt, A.; Smith, D.M.; Oakes, N. The novel TRPV1 antagonist, AZV1, improves insulin sensitivity in ob/ob mice. Presented at Proceedings of European Associated for the Study of Diabetes, Stockholm, Sweden, 14–18 September 2015; (poster 599-P). Available online: https://www.researchgate.net/publication/313369150 (accessed on 10 July 2019).
- Qiagen. RNeasy Mini Handbook (4th Edition, June 2012). Available online: https://www.qiagen.com/es/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbc-bf9f6fa33e24&lang=en (accessed on 10 July 2019).
- Exiqon. Universal ProbeLibrary Exiqon. Available online: http://www.probelibrary.com (accessed on 10 July 2019).
- Gram, D.X.; Hansen, A.J.; Deacon, C.F.; Brand, C.L.; Ribel, U.; Wilken, M.; Carr, R.D.; Svendsen, O.; Ahren, B. Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV. Eur. J. Pharmacol. 2005, 509, 211–217. [Google Scholar] [CrossRef] [PubMed]
- Caterina, M.J.; Julius, D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 2001, 24, 487–517. [Google Scholar] [CrossRef] [PubMed]
- Szallasi, A.; Cortright, D.N.; Blum, C.A.; Eid, S.R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 2007, 6, 357–372. [Google Scholar] [CrossRef] [PubMed]
- Di Marzo, V.; Blumberg, P.M.; Szallasi, A. Endovanilloid signalling in pain. Curr. Opin. Neurobiol. 2002, 12, 372–379. [Google Scholar] [CrossRef]
- Smart, D.; Gunthorpe, M.J.; Jerman, J.C.; Nasir, S.; Gray, J.; I Muir, A.; Chambers, J.K.; Randall, A.D.; Davis, J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 2000, 129, 227–230. [Google Scholar] [CrossRef] [Green Version]
- Lundberg, J.M.; Saria, A. Capsaicin-induced desensitization of airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature 1983, 302, 251–253. [Google Scholar] [CrossRef]
- André, E.; Campi, B.; Materazzi, S.; Trevisani, M.; Amadesi, S.; Massi, D.; Creminon, C.; Vaksman, N.; Nassini, R.; Civelli, M.; et al. Cigarette smoke–induced neurogenic inflammation is mediated by α,β-unsaturated aldehydes and the TRPA1 receptor in rodents. J. Clin. Investig. 2008, 118, 2574–2582. [Google Scholar] [CrossRef]
- Grimbsby, J.; Sarabu, R.; Corbett, W.L.; Haynes, N.E.; Bizzarro, F.T.; Coffey, J.W.; Guertin, K.R.; Hilliard, D.W.; Kester, R.F.; Mahaney, P.E.; et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003, 301, 370–373. [Google Scholar] [CrossRef]
- Pogatzki-Zahn, E.M.; Shimizu, I.; Caterina, M.; Raja, S.N. Heat hyperalgesia after incision requires TRPV1 and is distinct from pure inflammatory pain. Pain 2005, 115, 296–307. [Google Scholar] [CrossRef] [PubMed]
- Iida, T.; Shimizu, I.; Nealen, M.L.; Campbell, A.; Caterina, M. Attenuated fever in mice lacking TRPV1. Neurosci. Lett. 2005, 378, 28–33. [Google Scholar] [CrossRef] [PubMed]
- Kanizsai, P.; Garami, A.; Solymar, M.; Szolcsányi, J.; Szelényi, Z. Energetics of fasting heterothermia in TRPV1-KO and wild type mice. Physiol. Behav. 2009, 96, 149–154. [Google Scholar] [CrossRef] [PubMed]
- Garami, A.; Pakai, E.; Oliveira, D.L.; Steiner, A.A.; Wanner, S.P.; Almeida, M.C.; Lesnikov, V.A.; Gavva, N.R.; Romanovsky, A.A. Thermoregulatory Phenotype of the Trpv1 Knockout Mouse: Thermoeffector Dysbalance with Hyperkinesis. J. Neurosci. 2011, 31, 1721–1733. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moran, M.M.; Szallasi, A. Targeting nociceptive Transient Receptor Potential channels to treat chronic pain: The current state of the field. Br. J. Pharmacol. 2018, 175, 2185–2203. [Google Scholar] [CrossRef]
- Lee, Y.; Hong, S.; Cui, M.; Sharma, P.K.; Lee, J.; Choi, S. Transient receptor potential vanilloid 1 antagonists: A patent review (2011–2014). Exp. Opin. Ther. Pat. 2015, 25, 291–318. [Google Scholar] [CrossRef]
- Khalil, M.; Alliger, K.; Weidinger, C.; Yerinde, C.; Wirtz, S.; Becker, C.; Engel, M.A. Functional Role of Transient Receptor Potential Channels in Immune Cells and Epithelia. Front. Immunol. 2018, 9. [Google Scholar] [CrossRef]
- Fernandes, E.S.; Liang, L.; Smillie, S.-J.; Kaiser, F.; Purcell, R.; Rivett, D.W.; Alam, S.; Howat, S.; Collins, H.; Thompson, S.J.; et al. TRPV1 Deletion Enhances Local Inflammation and Accelerates the Onset of Systemic Inflammatory Response Syndrome. J. Immunol. 2012, 188, 5741–5751. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Wang, D.H. Aggravated renal inflammatory responses in TRPV1 gene knockout mice subjected to DOCA-salt hypertension. Am. J. Physiol. Physiol. 2009, 297, F1550–F1559. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Wang, D.H. TRPV1 Ablation Aggravates Inflammatory Responses and Organ Damage during Endotoxic Shock. Clin. Vaccine Immunol. 2013, 20, 1008–1015. [Google Scholar] [CrossRef] [Green Version]
- Cui, J.; Himms-Hagen, J. Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats. Am. J. Physiol. Integr. Comp. Physiol. 1992, 262, R568–R573. [Google Scholar] [CrossRef] [PubMed]
- Motter, A.L.; Ahern, G.P. TRPV1-null mice are protected from diet-induced obesity. FEBS Lett. 2008, 582, 2257–2262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marshall, N.J.; Liang, L.; Bodkin, J.; Dessapt-Baradez, C.; Nandi, M.; Collot-Teixeira, S.; Smillie, S.-J.; Lalgi, K.; Fernandes, E.S.; Gnudi, L.; et al. A Role for TRPV1 in Influencing the Onset of Cardiovascular Disease in Obesity. Hypertension 2013, 61, 246–252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wanner, S.P.; Garami, A.; Romanovsky, A.A. Hyperactive when young, hypoactive and overweight when aged: Connecting the dots in the story about locomotor activity, body mass, and aging in Trpv1 knockout mice. Aging 2011, 3, 450–454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, E.; Jung, D.Y.; Kim, J.H.; Patel, P.R.; Hu, X.; Lee, Y.; Azuma, Y.; Wang, H.-F.; Tsitsilianos, N.; Shafiq, U.; et al. Transient receptor potential vanilloid type-1 channel regulates diet-induced obesity, insulin resistance, and leptin resistance. FASEB J. 2015, 29, 3182–3192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Riera, C.E.; Huising, M.O.; Follett, P.; Leblanc, M.; Halloran, J.; Van Andel, R.; Filho, C.D.D.M.; Merkwirth, C.; Dillin, A. TRPV1 Pain Receptors Regulate Longevity and Metabolism by Neuropeptide Signaling. Cell 2014, 157, 1023–1036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Varghese, S.; Kubatka, P.; Rodrigo, L.; Gazdikova, K.; Caprnda, M.; Fedotova, J.; Zulli, A.; Kruzliak, P.; Büsselberg, D. Chili pepper as a body weight-loss food. Int. J. Food Sci. Nutr. 2017, 68, 392–401. [Google Scholar] [CrossRef] [PubMed]
- Zheng, J.; Zheng, S.; Feng, Q.; Zhang, Q.; Xiao, X. Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications. Biosci. Rep. 2017, 37. [Google Scholar] [CrossRef]
- Geppetti, P.; Nassini, R.; Materazzi, S.; Benemei, S. The concept of neurogenic inflammation. BJU Int. 2008, 101, 2–6. [Google Scholar] [CrossRef]
- Bleich, D.; Chen, S.; Gu, J.L.; Nadler, J.L. The role of 12-lipoxygenase in pancreatic β-cells. Int. J. Mol. Med. 1998, 1, 265–272. [Google Scholar]
- Ninomiya, Y.; Tanuma, S.I.; Tsukimoto, M. Differences in the effects of four TRPV1 channel antagonists on liposaccharide-induced cytokine production and COX-2 expression in murine macrophages. Biochem. Biophys. Res. Commun. 2017, 484, 668–674. [Google Scholar] [CrossRef] [PubMed]
- Obi, S.; Nakajima, T.; Hasegawa, T.; Kikuchi, H.; Oguri, G.; Takahashi, M.; Nakamura, F.; Yamasoba, T.; Sakuma, M.; Toyoda, S.; et al. Heat induces interleukin-6 in skeletal muscle cells via TRPV1/PKC/CREB pathways. J. Appl. Physiol. 2017, 122, 683–694. [Google Scholar] [CrossRef] [PubMed]
- Kang, S.M.; Han, S.; Oh, J.-H.; Lee, Y.M.; Park, C.-H.; Shin, C.-Y.; Lee, D.H.; Chung, J.H. A synthetic peptide blocking TRPV1 activation inhibits UV-induced skin responses. J. Dermatol. Sci. 2017, 88, 126–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, W.X.; Yu, F.; Sanchez, R.M.; Liu, Y.Q.; Min, J.W.; Hu, J.J.; Bsoul, N.B.; Han, S.; Yin, J.; Liu, W.H. TRPV1 promotes repetitive febrile seizures by pro-inflammatory cytokines in immature brain. Brain Behav. Immun. 2015, 48, 68–77. [Google Scholar] [CrossRef]
- Zanos, T.P.; Silverman, H.A.; Levy, T.; Tsaava, T.; Battinelli, E.; Lorraine, P.W.; Ashe, J.M.; Chavan, S.S.; Tracey, K.J.; Bouton, C.E. Identification of cytokine-specific sensory neural signals by decoding murine vagus nerve activity. Proc. Natl. Acad. Sci. USA 2018, 115, E4843–E4852. [Google Scholar] [CrossRef] [Green Version]
- Wang, P.; Yan, Z.; Zhong, J.; Chen, J.; Ni, Y.; Li, L.; Ma, L.; Zhao, Z.; Liu, D.; Zhu, Z. Transient Receptor Potential Vanilloid 1 Activation Enhances Gut Glucagon-Like Peptide-1 Secretion and Improves Glucose Homeostasis. Diabetes 2012, 61, 2155–2165. [Google Scholar] [CrossRef] [Green Version]
- Gram, D.X.; Hansen, A.J. Pila Pharma. Inhibition of the activity of the capsaicin receptor in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or insulin resistance. U.S. Patent 8,455,504 B2, 4 June 2013. [Google Scholar]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gram, D.X.; Fribo, J.; Nagy, I.; Gotfredsen, C.; Charrua, A.; Hansen, J.B.; Hansen, A.J.; Szallasi, A. TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation? Med. Sci. 2019, 7, 82. https://doi.org/10.3390/medsci7080082
Gram DX, Fribo J, Nagy I, Gotfredsen C, Charrua A, Hansen JB, Hansen AJ, Szallasi A. TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation? Medical Sciences. 2019; 7(8):82. https://doi.org/10.3390/medsci7080082
Chicago/Turabian StyleGram, Dorte X., Josefine Fribo, Istvan Nagy, Carsten Gotfredsen, Ana Charrua, John B. Hansen, Anker J. Hansen, and Arpad Szallasi. 2019. "TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation?" Medical Sciences 7, no. 8: 82. https://doi.org/10.3390/medsci7080082